SIGA
Closed
Siga Technologies Inc
6.49
-0.03 (-0.46%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 6.52
Day's Range: 6.34 - 6.6
Send
sign up or login to leave a comment!
When Written:
5.94
SIGA Technologies Inc is a biotechnology company that focuses on the development and commercialization of vaccines, therapeutics, and diagnostics for infectious diseases. The company was founded in 1995 and is headquartered in New York City, USA.
SIGA Technologies is primarily known for its development of smallpox antiviral drugs. Its lead product, TPOXX, is the first and only FDA-approved smallpox antiviral drug for the treatment of smallpox. TPOXX is also being evaluated for the treatment of other orthopoxvirus infections such as monkeypox and cowpox.
The company has also developed a broad-spectrum antiviral drug, ST-669, which has shown efficacy against a range of viral infections including influenza, Ebola, and Zika.
In addition to its antiviral drug development, SIGA Technologies is also working on the development of vaccines for infectious diseases such as Lassa fever and filoviruses.
SIGA Technologies has partnerships with various government agencies and organizations, including the US Department of Defense, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA).
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
SIGA Technologies is primarily known for its development of smallpox antiviral drugs. Its lead product, TPOXX, is the first and only FDA-approved smallpox antiviral drug for the treatment of smallpox. TPOXX is also being evaluated for the treatment of other orthopoxvirus infections such as monkeypox and cowpox.
The company has also developed a broad-spectrum antiviral drug, ST-669, which has shown efficacy against a range of viral infections including influenza, Ebola, and Zika.
In addition to its antiviral drug development, SIGA Technologies is also working on the development of vaccines for infectious diseases such as Lassa fever and filoviruses.
SIGA Technologies has partnerships with various government agencies and organizations, including the US Department of Defense, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA).
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!